However, Narita et al. demonstrated that a blockade of IL-6 signaling by anti-IL6 receptor antibody exerted an antitumor effect through the down-modulation of arginase-1 activity and up-regulation of MHC class II expression on tumor-associated CD11c+ dendritic cells [43]. Here, IL6 is linked to neoplasm.